Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

A differentiation antigen commonly expressed on melanoma cells, gp100 is the target of infiltrating T cells. We conducted a phase I randomized cross-over trial of melanoma patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yuan, Jianda, Ku, Geoffrey Y., Gallardo, Humilidad F., Orlandi, Francesca, Manukian, Gregor, Rasalan, Teresa S., Xu, Yinyan, Li, Hao, Vyas, Shachi, Mu, Zhenyu, Chapman, Paul B., Krown, Susan E., Panageas, Katherine, Terzulli, Stephanie L., Old, Lloyd J., Houghton, Alan N., Wolchok, Jedd D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Academy of Cancer Immunology 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2888533/
https://ncbi.nlm.nih.gov/pubmed/19496531
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge